Featured Publications
Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension
Phillips RA, Xu J, Peterson LE, Arnold RM, Diamond JA, Schussheim AE. Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension. Journal Of The American College Of Cardiology 2018, 71: 1601-1610. PMID: 29525494, DOI: 10.1016/j.jacc.2018.01.074.Peer-Reviewed Original ResearchConceptsSignificant serious adverse eventsPrimary outcome eventIntensive treatment groupCVD riskOutcome eventsHarm ratioIntensive treatmentTreatment groupsTreatment guidelinesAmerican CollegeCardiology/American Heart AssociationFuture cardiovascular disease riskCox proportional hazards modelBaseline CVD riskQuartiles of baselineSerious adverse eventsBlood pressure treatmentCardiovascular disease riskAmerican Heart AssociationProportional hazards modelLower ratesSPRINT populationAdverse eventsCardiovascular riskPrimary outcome
2022
Short-Term Outcomes After Myopericarditis Related to COVID-19 Vaccination
Pareek M, Steele J, Asnes J, Baldassarre L, Casale L, Desai N, Elder R, Faherty E, Ferguson I, Fishman R, Ghazizadeh Z, Glick L, Hall E, Khera R, Kokkinidis D, Kwan J, O'Marr J, Schussheim A, Tuohy E, Wang Y, Spatz E, Jacoby D, Miller E. Short-Term Outcomes After Myopericarditis Related to COVID-19 Vaccination. JACC Cardiovascular Imaging 2022, 15: 2002-2005. PMID: 36357140, PMCID: PMC9094612, DOI: 10.1016/j.jcmg.2022.03.026.Peer-Reviewed Case Reports and Technical Notes
2011
Dipyridamole-Associated Shock and Pulmonary Edema
Dioverti M, Fishman R, Moskowitz R, Arias SA, Nair S, Lall P, Schussheim AE, Zarich S, Manthous C. Dipyridamole-Associated Shock and Pulmonary Edema. Annals Of Pharmacotherapy 2011, 45: 1027-1027. PMID: 21672887, DOI: 10.1345/aph.1p734.Peer-Reviewed Original ResearchConceptsNoncardiogenic pulmonary edemaDipyridamole myocardial scintigraphyPulmonary edemaSevere pulmonary edemaCardiopulmonary collapseMyocardial scintigraphyNew left ventricular dysfunctionPositive end-expiratory pressureObjective causality assessmentLeft ventricular dysfunctionEnd-expiratory pressureMechanism of shockFulminant shockInvasive ventilationMultiple vasopressorsCardiovascular collapseHypovolemic shockShock refractoryCase seriesDipyridamole infusionEchocardiography resultsEndotracheal intubationIntravenous dipyridamoleContinuous infusionIntravenous infusion
2003
Detecting Acute Coronary Syndrome in the Emergency Department With Cardiac Magnetic Resonance Imaging
Kwong RY, Schussheim AE, Rekhraj S, Aletras AH, Geller N, Davis J, Christian TF, Balaban RS, Arai AE. Detecting Acute Coronary Syndrome in the Emergency Department With Cardiac Magnetic Resonance Imaging. Circulation 2003, 107: 531-537. PMID: 12566362, DOI: 10.1161/01.cir.0000047527.11221.29.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAngina, UnstableChest PainCoronary DiseaseDiagnosis, DifferentialElectrocardiographyEmergency Service, HospitalFemaleFollow-Up StudiesHumansLikelihood FunctionsLogistic ModelsMagnetic Resonance ImagingMaleMiddle AgedMyocardial InfarctionPredictive Value of TestsProspective StudiesROC CurveSensitivity and SpecificityTroponinConceptsAcute coronary syndromeStrict ECG criteriaTIMI risk scoreCoronary syndromeChest painEmergency departmentPeak troponinAbnormal ECGRisk scoreECG criteriaProbable acute coronary syndromeCardiac MRIMultivariate logistic regression analysisCardiac magnetic resonance imagingDiagnostic operating characteristicsHours of presentationTriage of patientsAcute myocardial infarctionLogistic regression analysisCurrent diagnostic strategiesMagnetic resonance imagingUnstable anginaConsecutive patientsVentricular functionClinical parameters
2001
Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension
Schussheim A, Diamond J, Phillips R. Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension. The American Journal Of Cardiology 2001, 87: 61-65. PMID: 11137835, DOI: 10.1016/s0002-9149(00)01273-x.Peer-Reviewed Original ResearchConceptsMidwall fractional shorteningLV mass regressionAntihypertensive therapyAsymptomatic hypertensionVentricular hypertrophyMidwall functionMass regressionEarly hypertensive heart diseaseConventional echocardiographic parametersHypertensive heart diseaseLeft ventricular massPotential beneficial effectsEchocardiographic parametersFractional shorteningHypertensive personsIndependent predictorsVentricular massDrug therapyMyocardial performanceHeart diseaseCardiac performanceVentricular geometryChamber functionPatientsTherapy
1999
Antibiotics for Myocardial Infarction?
Schussheim A, Fuster V. Antibiotics for Myocardial Infarction? Drugs 1999, 57: 283-291. PMID: 10193683, DOI: 10.2165/00003495-199957030-00002.Peer-Reviewed Original ResearchConceptsInfectious organismsAtherosclerotic lesionsFuture large-scale clinical trialsLarge-scale clinical trialsRecent pilot trialRecurrent coronary eventsCoronary artery diseaseElaboration of cytokinesEvidence of infectionVascular smooth muscle cellsCoronary artery plaquesRisk of restenosisSmooth muscle cellsDirect local effectsActive atherosclerosisCoronary eventsCoronary interventionInflammatory mechanismsArtery diseaseHypercoagulable statePathological examinationAtherosclerotic processSeroepidemiological investigationCoronary endotheliumArtery plaques
1998
Midwall fractional shortening is an independent predictor of left ventricular diastolic dysfunction in asymptomatic patients with systemic hypertension
Schussheim A, Diamond J, Jhang J, Phillips R. Midwall fractional shortening is an independent predictor of left ventricular diastolic dysfunction in asymptomatic patients with systemic hypertension. The American Journal Of Cardiology 1998, 82: 1056-1059. PMID: 9817481, DOI: 10.1016/s0002-9149(98)00558-x.Peer-Reviewed Original ResearchConceptsMidwall fractional shorteningAbnormal diastolic functionMidwall shorteningHypertensive patientsSystolic functionDiastolic functionFractional shorteningDiastolic dysfunctionBlood pressureIndependent predictorsSystolic performanceEndocardial shorteningFiber shorteningLeft ventricular systolic performanceDepressed midwall shorteningHealthy hypertensive patientsLV diastolic abnormalitiesLV inflow velocityNormal midwall shorteningTarget organ damageVentricular diastolic dysfunctionIsovolumic relaxation timeLV systolic functionHigh blood pressureVentricular systolic performanceAntithrombotic therapy and venous graft disease.
Schussheim AE, Fuster V. Antithrombotic therapy and venous graft disease. Current Opinion In Cardiology 1998, 13: 459. PMID: 9822880, DOI: 10.1097/00001573-199811000-00012.Peer-Reviewed Original ResearchConceptsVenous graft diseaseGraft diseaseLow-dose oral anticoagulationAggressive cholesterol reductionEfficacy of antithromboticsCoronary artery bypassSymptom-free survivalTiming of therapyPotent antithrombotic agentOral anticoagulationAntithrombotic therapyArtery bypassGraft occlusionPreventive therapyAntiplatelet agentsHemostatic factorsAntithrombotic agentsCholesterol reductionTherapyFirst dayPatientsSurgeryDisease developmentDiseaseFirst yearIs digoxin a designer oestrogen?
Schussheim D, Schussheim A. Is digoxin a designer oestrogen? The Lancet 1998, 351: 1734. PMID: 9734913, DOI: 10.1016/s0140-6736(05)77771-0.Peer-Reviewed Original Research
1997
Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease
Schussheim A, Fuster V. Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease. Progress In Cardiovascular Diseases 1997, 40: 205-238. PMID: 9406677, DOI: 10.1016/s0033-0620(97)80035-7.Peer-Reviewed Original ResearchConceptsThrombus formationAntithrombotic agentsAnticoagulant agentsCardiac diseaseUse of antiplateletUnderstanding of pathogenesisRational approachAntithrombotic therapyAntithrombotic approachAntiplatelet agentsConcomitant useDisease entityRelative riskHigh riskLower riskThrombosisHemostatic processAntiplateletAntithromboticsRiskDiseaseMedium riskAgentsThromboembolismAnticoagulantsUsefulness of Subnormal Midwall Fractional Shortening in Predicting Left Ventricular Exercise Dysfunction in Asymptomatic Patients With Systemic Hypertension
Schussheim A, Devereux R, de Simone G, Borer J, Herrold E, Laragh J. Usefulness of Subnormal Midwall Fractional Shortening in Predicting Left Ventricular Exercise Dysfunction in Asymptomatic Patients With Systemic Hypertension. The American Journal Of Cardiology 1997, 79: 1070-1074. PMID: 9114766, DOI: 10.1016/s0002-9149(97)00049-0.Peer-Reviewed Original ResearchConceptsMidwall fractional shorteningAsymptomatic hypertensive patientsLV ejection fractionFractional shorteningBlood pressureHypertensive patientsEjection fractionHigher mean diastolic blood pressureExtracardiac target organ damageHigher urinary protein excretionLower midwall fractional shorteningMean diastolic blood pressureLV functional reserveSerum creatinine levelsTarget organ damageUrinary protein excretionDiastolic blood pressureSystolic blood pressureHigher LV massBody mass indexIdentification of patientsExercise dysfunctionAsymptomatic patientsSystemic hypertensionCreatinine levels
1993
Cardiac nuclear magnetic resonance spectroscopy
Schussheim A, Kantor H. Cardiac nuclear magnetic resonance spectroscopy. Coronary Artery Disease 1993, 4: 361-370. PMID: 8261209, DOI: 10.1097/00019501-199304000-00008.Peer-Reviewed Original Research